Agenus (FRA:AJ8) Accumulated Depreciation : €-59.9 Mil (As of Mar. 2024)

View and export this data going back to . Start your Free Trial

What is Agenus Accumulated Depreciation?

Note: A negative number here means the assets are depreciated. When depricates more, the absolute value gets bigger.

Agenus's quarterly accumulated depreciation declined from Sep. 2023 (€-56.9 Mil) to Dec. 2023 (€-56.8 Mil) but then increased from Dec. 2023 (€-56.8 Mil) to Mar. 2024 (€-59.9 Mil).

Agenus's annual accumulated depreciation increased from Dec. 2021 (€-44.7 Mil) to Dec. 2022 (€-51.0 Mil) and increased from Dec. 2022 (€-51.0 Mil) to Dec. 2023 (€-56.8 Mil).

Agenus Accumulated Depreciation Historical Data

The historical data trend for Agenus's Accumulated Depreciation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Agenus Accumulated Depreciation Chart

Agenus Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accumulated Depreciation

Get a 7-Day Free Trial

-38.58

-38.80

-44.73

-51.05

-56.80

Agenus Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Accumulated Depreciation	Get a 7-Day Free Trial															-52.42	-53.99	-56.92	-56.80	-59.87

Agenus Accumulated Depreciation Calculation

The cumulative depreciation of an asset up to a single point in its life. Regardless of the method used to calculate it, the depreciation of an asset during a single period is added to the previous period's accumulated depreciation to get the current accumulated depreciation.

Agenus Accumulated Depreciation Related Terms

Thank you for viewing the detailed overview of Agenus's Accumulated Depreciation provided by GuruFocus.com. Please click on the following links to see related term pages.

Agenus (FRA:AJ8) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Agenus Inc (FRA:AJ8) » Definitions » Accumulated Depreciation

Comparable Companies

Traded in Other Exchanges

AGEN:USA AJ81:Germany

Address

3 Forbes Road, Lexington, MA, USA, 02421

Website

https://www.agenusbio.com

Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).

Agenus (FRA:AJ8) Headlines

No Headlines